Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study

IMPORTANCE: An oral treatment for neovascular age-related macular degeneration would be less burdensome than repeated intravitreous injections. X-82 is an oral tyrosine kinase inhibitor active against vascular endothelial growth factor (VEGF) and platelet-derived growth factor. OBJECTIVE: To underta...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA ophthalmology 2017-07, Vol.135 (7), p.761-767
Hauptverfasser:	Jackson, Timothy L, Boyer, David, Brown, David M, Chaudhry, Nauman, Elman, Michael, Liang, Chris, O’Shaughnessy, Denis, Parsons, Edward C, Patel, Sunil, Slakter, Jason S, Rosenfeld, Philip J
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Dose-Response Relationship, Drug Enzyme Inhibitors - administration & dosage Female Fluorescein Angiography Follow-Up Studies Fundus Oculi Humans Macular Degeneration - diagnosis Macular Degeneration - drug therapy Macular Degeneration - physiopathology Male Middle Aged Online First Original Investigation Protein-Tyrosine Kinases - antagonists & inhibitors Retrospective Studies Time Factors Tomography, Optical Coherence Treatment Outcome Visual Acuity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!